Gadeta is a company that works with T cell receptors in order to make treatments for advanced malignancies. The company was founded by Dr. Mark de Boer and Dr. Jurgen Kuball, in 2015, in Utrecht, Utrecht, The Netherlands.
The company works with hematological and solid tumor cells to discover treatments to combat malignant cancers. Gadeta has created therapeutics with the potential for combating and destroying both blood related and solid cancer. The cells they use are known as TEGs, standing for T-cells engineered to Express a defined Gamma delta TCR (TEGs). Their process uses cells that are carriers with high proliferation activity, and adds them to optimized for killing malignant cells, provide GMP grade lentrival gene transfers, make an enrichment of engineered immune cells in a closed system, which then creates a metabolic targeting of the cancer stem cell.
Gadeta's technology platform is based on the founder Dr. Jurgen Huball's discovery, and utilizes receptors displayed in anti-cancer reactivity to sense metabolic changes in cancer cells.
Dr. Mark de Boer
Dr. Tolleiv Trimborn
Gilead brings Medicxi’s tiny Gadeta into the cell therapy fold, hunting a way to pick the lock on solid tumors
Gilead’s Kite and Netherlands’ Gadeta Ink Strategic T-Cell Collaboration
Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors
Documentaries, videos and podcasts
Dr. Mark de Boer
Utrecht, Utrecht, The Netherlands
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.